| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/10/2011 | WO2011026641A1 Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| 03/10/2011 | WO2011026447A1 New antibiotic containing simulacrum antibody, preparation method and application thereof |
| 03/10/2011 | WO2011026351A1 A cyanovirin n mutant, modified derivative and uses thereof |
| 03/10/2011 | WO2011026234A1 Clarithromycin extended-release tablet |
| 03/10/2011 | WO2011007153A8 Improvements in and relating to colon cleansing compositions |
| 03/10/2011 | WO2011003622A8 Method for the production of variable domains |
| 03/10/2011 | WO2010151653A9 Terpene glycosides and their combinations as solubilizing agents |
| 03/10/2011 | WO2010147302A3 Novel intermediates of voriconazole and preparation method of voriconazole using the same |
| 03/10/2011 | WO2010141586A3 Therapeutic ophthalmic emulsions |
| 03/10/2011 | WO2010135527A9 Elastin for soft tissue augmentation |
| 03/10/2011 | WO2010087986A3 Resuscitation fluid |
| 03/10/2011 | US20110060310 Intracutaneous injection |
| 03/10/2011 | US20110060020 Process for release of biologically active species |
| 03/10/2011 | US20110060016 Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
| 03/10/2011 | US20110059985 Novel formulation |
| 03/10/2011 | US20110059927 Calcium Formate For Use As A Dietary Supplement |
| 03/10/2011 | US20110059175 Enhancing solubility and dissolution rate of poorly soluble drugs |
| 03/10/2011 | US20110059158 Charged phospholipid compositions and methods for their use |
| 03/10/2011 | US20110059144 Encapsulated hydrophobic actives via interfacial polymerization |
| 03/10/2011 | US20110059127 Use of mutant hiv-1 protease or siv protease as an adjuvant |
| 03/10/2011 | US20110059010 Dual phase drug release system |
| 03/10/2011 | CA2848827A1 Silicone modified fatty acids, method of preparation and usage thereof |
| 03/10/2011 | CA2805749A1 Pharmaceutical formulations and methods of use |
| 03/10/2011 | CA2773037A1 Clarithromycin extended-release tablet |
| 03/10/2011 | CA2772912A1 Stable formulation of factor viii |
| 03/10/2011 | CA2772660A1 Delivery of therapeutic agents using oligonucleotide-modified nanoparticles as carriers |
| 03/10/2011 | CA2772628A1 Dual variable domain immunoglobulins and uses thereof |
| 03/10/2011 | CA2772622A1 Ketorolac tromethamine compositions for treating or preventing ocular pain |
| 03/10/2011 | CA2772215A1 Polymer compositions |
| 03/10/2011 | CA2772191A1 Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same |
| 03/10/2011 | CA2772057A1 Targeted delivery using tissue-specific peptidomimetic ligands |
| 03/10/2011 | CA2772051A1 Coagulation factor ix compositions and methods of making and using same |
| 03/10/2011 | CA2771999A1 Coagulation factor vii compositions and methods of making and using same |
| 03/10/2011 | CA2771900A1 Tumoricidal, bactericidal, or viricidal macrophage activation |
| 03/10/2011 | CA2771254A1 Novel diagnostic agents for the non-invasive in vivo imaging of aminopeptidase n (apn/cd13) |
| 03/10/2011 | CA2765421A1 Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| 03/09/2011 | EP2293067A2 T1R hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds |
| 03/09/2011 | EP2292666A2 Neoplasm specific antibodies and uses thereof |
| 03/09/2011 | EP2292651A1 Methods and compositions for the prevention and treatment of anemia |
| 03/09/2011 | EP2292650A1 Methods and compositions for the prevention and treatment of anemia |
| 03/09/2011 | EP2292632A2 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| 03/09/2011 | EP2292275A2 Protecting therapeutic compositions from host-mediated inactivation |
| 03/09/2011 | EP2292273A2 Remodeling and glycoconjugation of peptides |
| 03/09/2011 | EP2292272A2 Polypeptide protracting tags comprising a tetrazole moiety |
| 03/09/2011 | EP2292271A2 Remodelling and glycoconjugation of an antibody |
| 03/09/2011 | EP2292270A1 Drug carrier |
| 03/09/2011 | EP2292263A2 Compositions and methods for stabilizing biological molecules upon lyophilization |
| 03/09/2011 | EP2292239A2 Remedies for diseases to be applied to eye |
| 03/09/2011 | EP2292234A1 Compositions comprising quinazoline derivatives, preparation methods and uses thereof |
| 03/09/2011 | EP2292225A1 Dosage form comprising taxol in crystalline form |
| 03/09/2011 | EP2292216A2 Stable pharmaceutical composition containing factor VIII |
| 03/09/2011 | EP2292211A2 Mucoadhesive pharmaceutical formulations |
| 03/09/2011 | EP2291406A1 An anti-cancer cytotoxic monoclonal antibody |
| 03/09/2011 | EP2291390A1 New optically pure compounds for improved therapeutic efficiency |
| 03/09/2011 | EP2291350A2 Compositions and methods for preparing and using same |
| 03/09/2011 | EP2291199A2 Capsulating system binding to nucleolin |
| 03/09/2011 | EP2291198A2 Vesicles comprising an amphiphilic block copolymer for use in epithelial delivery |
| 03/09/2011 | EP2291185A1 Octenidine composition |
| 03/09/2011 | EP2291180A1 Anhydrous depigmenting compositions comprising, within the fatty phase, a solubilized phenolic derivative and a retinoid |
| 03/09/2011 | EP2291179A2 Novel anhydrous depigmenting compositions comprising a solubilized phenolic derivative |
| 03/09/2011 | EP2291178A2 Controlled release formulations of pramipexole |
| 03/09/2011 | EP1991271B1 Anticoagulant antithrombotic dual inhibitors comprising a biotin label |
| 03/09/2011 | EP1888122B1 A method for preparing a stable immunogenic product comprising antigenic heterocomplexes of tnf alpha and a carrier protein |
| 03/09/2011 | EP1888119B1 Pegylated g-csf polypeptides and methods of producing same |
| 03/09/2011 | EP1842857B1 Mutant interferon proteins and use thereof |
| 03/09/2011 | EP1830887B1 Antithrombotic dual inhibitors comprising a biotin residue |
| 03/09/2011 | EP1732602B1 Detecting the mcsp-surface expression of a cell |
| 03/09/2011 | EP1722759B1 Composition containing chitosan and a polyol-phosphate or a sugar-phosphate |
| 03/09/2011 | EP1594548B1 Anthracycline-anti-cd74 antibody conjugates |
| 03/09/2011 | EP1499297B1 Pharmaceutical formulation comprising atorvastatin calcium |
| 03/09/2011 | EP1315513B1 "pseudo"-native chemical ligation |
| 03/09/2011 | EP1194113B1 Use of bioactive glass as a preservative for cosmetic and pharmaceutical preparations |
| 03/09/2011 | EP1135178B1 Polymeric coatings with controlled delivery active agents |
| 03/09/2011 | CN1798549B Stabilized aerosol dispersions |
| 03/09/2011 | CN101984757A Solid silicic acid preparation |
| 03/09/2011 | CN101983977A Method for synthesizing polysorbate-80 for injection |
| 03/09/2011 | CN101983723A Slow-release medicine carrier |
| 03/09/2011 | CN101983668A Shiqi exogenous traditional Chinese medicine tablet |
| 03/09/2011 | CN101983667A Shiqi exogenous traditional Chinese medicine beverage |
| 03/09/2011 | CN101983630A Composition for treating salpingitis of birds and preparation method thereof |
| 03/09/2011 | CN101983628A Mezlocillin sodium and sulbactam sodium drug composite microsphere injection |
| 03/09/2011 | CN101513409B Pharmaceutical composition of cephalexin |
| 03/09/2011 | CN101444510B Pharmaceutical preparation containing voriconazole and preparation method thereof |
| 03/09/2011 | CN101284009B Cefoperazone sodium and sulbactam sodium combination and preparation method thereof |
| 03/08/2011 | US7902164 Gene expression inhibition; sustained release; for reduction of neuronal cell death, inflammation, and scar formation; improves wound healing, skin rejuvenation and thickening |
| 03/08/2011 | US7902161 Oligonucleotides derived from mycobacterium for stimulating immune function, treating immune-related diseases, atopic dermatitis and/or protecting normal immune cell |
| 03/08/2011 | US7902144 Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same |
| 03/08/2011 | US7901716 Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng |
| 03/08/2011 | US7901709 Active agent, a gel-phase lipid bilayer membrane of a phospholipid and a surface active agent contained in the bilayer membrane; increasing the percentage of active agent released at the phase transition temperature of the lipid bilayer |
| 03/08/2011 | US7901708 Liposomal apparatus and manufacturing methods |
| 03/08/2011 | US7901707 Biodegradable biocompatible implant and method of manufacturing same |
| 03/08/2011 | US7901695 Controlled release polymeric gels |
| 03/08/2011 | US7901687 Antibodies for the detection of Bacillus anthracis and vaccine against B. anthracis infections |
| 03/08/2011 | US7901674 Aldehyde-fixed platelets with internalized paramagnetic or magnetic nanoparticles |
| 03/08/2011 | CA2567807C Activated foam |
| 03/08/2011 | CA2557791C Controlled-release pharmaceutical composition and method for producing the same |
| 03/08/2011 | CA2529162C Disialoundecasaccharide chain asparagine/fatty acid amide and medical drug containing the same |
| 03/08/2011 | CA2510181C Administration of capsaicinoids |
| 03/08/2011 | CA2449217C Process for cleaning hard gelatine capsules |
| 03/08/2011 | CA2440355C Fibrate-statin combinations with reduced fed-fasted effects |